利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.024 秒)

    Prlz regulatory elements in the treatment of disease and the discovery of therapeutics
    2.
    发明申请
    Prlz regulatory elements in the treatment of disease and the discovery of therapeutics 审中-公开
    Prlz调节因素治疗疾病和发现治疗

    公开(公告)号：US20070015149A1

    公开(公告)日：2007-01-18

    申请号：US10510148

    申请日：2003-04-07

    申请人： Ruoxing Wang ,  Leland W. K. Chung

    发明人： Ruoxing Wang ,  Leland W. K. Chung

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  C12P21/06 ,  C07K14/82 ,  C07K16/30 ,  C40B30/06

    CPC分类号： C07K14/4702 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/82 ,  C07K16/3069 ,  C07K2319/00 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011

    摘要： The compositions and methods of the present invention are based, in part, on a gene designated prostate leucine zipper (PrLZ) and the sequences that mediate its expression. The presence of the leucine zipper indicates that PrLZ encodes a protein that interacts with other proteins. Methods to inhibit the activity of PrLZ by identifying and inhibiting the interaction between PrLZ and such binding partners are within the scope of the invention, as are methods of inhibiting PrLZ in other ways (by, for example, inhibiting its expression with antisense molecules or siRNAs or inhibiting its activity with, for example, anti-PrLZ antibodies). Such inhibition is useful in the treatment of cancers or dysplasias affecting PrLZ-positive tissues, such as those in the prostate.

    摘要翻译： 本发明的组合物和方法部分地基于称为前列腺亮氨酸拉链（PrLZ）的基因和介导其表达的序列。 亮氨酸拉链的存在表明PrLZ编码与其他蛋白质相互作用的蛋白质。 通过鉴定和抑制PrLZ与这种结合配偶体之间的相互作用来抑制PrLZ的活性的方法也在本发明的范围内，以其他方式抑制PrLZ的方法也是如此（例如通过用反义分子或siRNA抑制其表达 或用例如抗PrLZ抗体抑制其活性）。 这种抑制可用于治疗影响PrLZ阳性组织（例如前列腺中的那些）的癌症或发育不良。

    METHODS AND COMPOSITIONS FOR THE UTILIZATION AND TARGETING OF OSTEOMIMICRY
    6.
    发明申请
    METHODS AND COMPOSITIONS FOR THE UTILIZATION AND TARGETING OF OSTEOMIMICRY 审中-公开
    方法和组合物的使用和目标的OSTEOMIMICRY

    公开(公告)号：US20100015148A1

    公开(公告)日：2010-01-21

    申请号：US12343063

    申请日：2008-12-23

    申请人： Leland W. K. Chung ,  Wen-Chin Huang ,  Valerie Odero-Marah ,  Daqing Wu ,  Chia-Ling Hsieh ,  Haiyen Zhau

    发明人： Leland W. K. Chung ,  Wen-Chin Huang ,  Valerie Odero-Marah ,  Daqing Wu ,  Chia-Ling Hsieh ,  Haiyen Zhau

    IPC分类号： A61K39/395 ,  C12N5/02 ,  A61K31/7088 ,  C12Q1/68

    CPC分类号： G01N33/5011 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2833 ,  C07K2317/73 ,  C12N15/113 ,  C12N2310/14 ,  C12Q1/6886

    摘要： A method for interfering with osteomimetic properties of a cell includes introducing into the cell an osteomimecry-interfering compound, wherein said osteomimecry-interfering compound prevents or ameliorates the expression of the osteomimetic properties of said cell. A method for treating or ameliorating an osteotropic-related cancer or disorder in a subject includes administering to the subject an osteomimecry interfering compound. A method for identifying a compound that modulates the osteomimetic potential of a cell includes contacting a cell exhibiting osteomimetic potential with a test compound; measuring expression levels of one or more osteomimetic gene products in the cell in the presence and in the absence of the test compound; and identifying a compound that modulates the osteomimetic potential, wherein the compound changes the expression levels of one or more osteomimetic gene products in the cell.

    摘要翻译： 用于干扰细胞的骨模拟性质的方法包括向细胞中引入骨干哺乳干扰化合物，其中所述骨修复干扰化合物预防或改善所述细胞的骨模拟性质的表达。 用于治疗或改善受试者中的骨相关性癌症或病症的方法包括向受试者施用骨前体干扰化合物。 用于鉴定调节细胞的骨模拟潜力的化合物的方法包括使表现出骨骼发展潜力的细胞与测试化合物接触; 在存在和不存在测试化合物的情况下测量细胞中一种或多种骨模拟基因产物的表达水平; 以及鉴定调节所述骨模拟潜力的化合物，其中所述化合物改变所述细胞中一种或多种成骨细胞基因产物的表达水平。

    Utilization of osteocalcin promoter to deliver therapeutic genes to tumors
    7.
    发明授权
    Utilization of osteocalcin promoter to deliver therapeutic genes to tumors 失效
    利用骨钙素启动子向肿瘤递送治疗基因

    公开(公告)号：US06596534B1

    公开(公告)日：2003-07-22

    申请号：US09534414

    申请日：2000-03-23

    申请人： Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

    发明人： Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

    IPC分类号： A01N6300

    CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/008 ,  C12N2830/85

    摘要： A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.

    摘要翻译： 基于使用骨钙素启动子表达胸苷激酶的重组腺病毒的治疗剂可以血管内给药以治疗转移性癌症，包括骨肉瘤，乳腺癌，前列腺癌，眼黑素瘤或脑癌。 该药剂的系统性给药提供优于先前公开的局部直接给药的优选途径。 相同的治疗剂可以有效地用于良性病症的治疗，包括良性前列腺肥大和动脉硬化。

    Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
    8.
    发明授权
    Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis 失效
    骨和前列腺衍生的蛋白质因子影响前列腺癌的生长，分化和转移

    公开(公告)号：US5679636A

    公开(公告)日：1997-10-21

    申请号：US341297

    申请日：1994-11-15

    申请人： Leland W. K. Chung ,  James C. Chan ,  Christopher J. Logothetis

    发明人： Leland W. K. Chung ,  James C. Chan ,  Christopher J. Logothetis

    IPC分类号： A61K38/00 ,  C07K14/475 ,  C07K14/51 ,  C07K16/22 ,  A61K38/18 ,  A23J1/00

    CPC分类号： C07K16/22 ,  C07K14/475 ,  C07K14/51 ,  A61K38/00

    摘要： The role of tumor cell-host stromal interaction and stromal-specific growth factors in prostate cancer growth, progression and metastasis to the axial skeleton were investigated. Following co-inoculation of athymic mice with human prostate cancer cells (LNCaP) and various nontumorigenic fibroblasts, human prostate-like tumor formation was consistently induced by human bone (MS) fibroblasts (62%), embryonic rat urogenital sinus mesenchymal (rUGM) cells (31%) and Noble rat prostatic fibroblasts (17%), but not by NIH-3T3, normal rat kidney (NRK), or human lung CCD16 fibroblasts. Carcinomas formed preferentially in male hosts, demonstrating in vivo androgen sensitivity. A novel in vivo method in which a slowly adsorbed matrix (Gelfoam) was employed to deliver concentrated prostate and bone fibroblast-derived conditioned media was also found to induce LNCaP tumor formation in vivo. Such in vivo growth-promoting effects correlated with in vitro tests employing a soft agar colony-forming assay using rat prostate epithelial (NbE-1) cells as targets. A substantially purified human growth factor preparation is shown to contain distinct polypeptides with apparent M.sub.r s on SDS/PAGE of 227, 223, 218, 157, 90, 80, 48, and 20 kD, and to be distinct from bFGF. The human growth factor polypeptide of 157 kD was identified, in human bone marrow aspirates, by immunoblotting with the mAb MS 329.

    摘要翻译： 研究了肿瘤细胞宿主基质相互作用和基质特异性生长因子在前列腺癌生长，进展和转移到轴向骨骼中的作用。 在用人前列腺癌细胞（LNCaP）和各种非致瘤性成纤维细胞共同接种无胸腺小鼠后，人骨骼（MS）成纤维细胞（62％），胚胎大鼠泌尿生殖器窦间质（rUGM）细胞一致诱导人类前列腺样肿瘤形成 （31％）和Noble大鼠前列腺成纤维细胞（17％），而不是NIH-3T3，正常大鼠肾（NRK）或人肺CCD16成纤维细胞。 癌症优先在雄性宿主中形成，表现出体内雄激素敏感性。 使用缓慢吸附的基质（Gelfoam）用于递送浓缩的前列腺和骨成纤维细胞衍生的条件培养基的新型体内方法也诱导体内LNCaP肿瘤的形成。 这种体内生长促进作用与使用大鼠前列腺上皮（NbE-1）细胞作为靶标的软琼脂集落形成测定的体外测试相关。 显示基本上纯化的人生长因子制剂在SDS / PAGE上含有明确的多肽，分别为227,223,218,157,90,80,48和20kD，并且与bFGF不同。 通过用mAb MS 329的免疫印迹，在人骨髓抽吸物中鉴定出157kD的人生长因子多肽。